| Date Filed | Type | Description |
| 10/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/12/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 10/11/2023 |
8-A12B
| Form 8-A12B - Registration of securities [Section 12(b)]: |
| 10/11/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update Brisbane, CA, August 10, 2023 – Tempest Therapeutics, Inc. , a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2023 and provided a corporate update. “2023 continues to be a productive and potentially transformative year for Tempest,” said Stephen Brady, chief executive officer of Tempest. “In the second quarter, we presented data from our second clinical program, TPST-1495, the company’s novel dual EP2/EP4 antagonist designed to selectively modulate the prostaglandin pathway, both at ASCO and in a paper published in Cancer Research Communicati..." |
|
| 06/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Tempest Reports First Quarter 2023 Financial Results and Provides Business Update Brisbane, CA, May 10, 2023 – Tempest Therapeutics, Inc. , a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update. “The first few months of 2023 set the pace for what we believe will be a transformative year for Tempest,” said Stephen Brady, chief executive officer of Tempest. “Recently, we announced exciting early data showing that TPST-1120, the company’s PPAR⍺ antagonist, combined with standard of care in first-line HCC patients demonstrated clinically meaningful improvement in multiple categories, incl..." |
|
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/28/2023 |
8-K
| Quarterly results |
| 03/31/2023 |
8-K
| Other Events Interactive Data |
| 03/22/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Rock Springs Capital Management LP reports a 7.8% stake in Tempest Therapeutics, Inc. |
| 02/14/2023 |
SC 13G
| EcoR1 Capital, LLC reports a 10% stake in Tempest Therapeutics Inc. |
| 01/05/2023 |
4
| Whiting Samuel (Chief Medical Officer) has filed a Form 4 on Tempest Therapeutics, Inc.|
Txns:
| Granted 69,700 options to buy
@ $1.23, valued at
$85.7k
|
|
| 01/05/2023 |
4
| Dubensky Thomas W. (President) has filed a Form 4 on Tempest Therapeutics, Inc.|
Txns:
| Granted 102,700 options to buy
@ $1.23, valued at
$126.3k
|
|
| 01/05/2023 |
4
| Brady Stephen R (CEO) has filed a Form 4 on Tempest Therapeutics, Inc.|
Txns:
| Granted 177,300 options to buy
@ $1.23, valued at
$218.1k
|
|
| 01/05/2023 |
4
| Maestas Nicholas (VP of Strategy and Finance) has filed a Form 4 on Tempest Therapeutics, Inc.|
Txns:
| Granted 38,425 options to buy
@ $1.23, valued at
$47.3k
|
|
| 01/05/2023 |
4
| Trojanowski Justin (Corporate Controller) has filed a Form 4 on Tempest Therapeutics, Inc.|
Txns:
| Granted 20,300 options to buy
@ $1.23, valued at
$25k
|
|
| 12/29/2022 |
8-K
| Quarterly results |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results |
| 10/04/2022 |
4
| Trojanowski Justin (Corporate Controller) has filed a Form 4 on Tempest Therapeutics, Inc.|
Txns:
| Granted 2,500 options to buy
@ $1.85, valued at
$4.6k
|
|
| 10/04/2022 |
3
| Trojanowski Justin (Corporate Controller) has filed a Form 3 on Tempest Therapeutics, Inc. |
| 09/23/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
8-K
| Quarterly results |
|